Tüdőrák: vizsgálatok itt: Franciaország
318 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - 1. fázisNot yet taking people in FranciaországPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Lyon, Marseille, Toulouse Cedex 9
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 1. fázisTaking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Lyon, Paris, Saint-Herblain, Villejuif
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - 2. fázisTaking peopleA Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- Where
- Angers, Bordeaux, Lyon, Marseille
- Életkor
- 18 év and over
- People
- 48 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT07203053 · EU 2025-522288-13-00 - 2. fázisTaking peoplePhase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01
- Where
- Bordeaux, Brest, Caen Cedex 5, Créteil, Paris, Paris Cedex 20, Pierre-Bénite, Strasbourg Cedex, Villejuif
- Életkor
- 18 év and over
- People
- 100
- Run by
- Institut Gustave Roussy
See details and how to join2023-505924-71-00 - 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- Avignon, Brest, Creteil Cedex, Lille, Lyon, Marseille, Montpellier Cedex 5, Nantes Cedex 2, Paris, Paris Cedex 20, Rennes Cedex 9, Saint-Herblain, Strasbourg Cedex, Toulon Cedex 9, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Bron, Grenoble Cedex 9, Paris, Saint-Herblain, Vandoeuvre Les Nancy
- Életkor
- 18 év and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00 - No phaseNot yet taking people in FranciaországShort- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer
- Where
- Angers, Bobigny, Bordeaux, Clermont-Ferrand, Dijon, Le Plessis-Robinson, Lille, Lyon, Marseille, Nantes, Paris, Poitiers, Rennes, Rouen, Strasbourg, Suresnes, Toulouse, Tours
- Életkor
- 18 év and over
- People
- 2400
- Run by
- Fondation Hôpital Saint-Joseph
See details and how to joinNCT07828938 - 1/2. fázisTaking peopleA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Where
- Nice, Paris, Suresnes
- Életkor
- 18 év and over
- People
- 118 worldwide
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933 - 1/2. fázisTaking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Clichy, Nantes, Villejuif
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - 1. fázisTaking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Lyon, Marseille, Toulouse, Vandoeuvre Les Nancy Cedex
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - 4. fázisNot yet taking people in FranciaországPharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
- Where
- Nice Cedex 2
- Életkor
- 18 év and over
- People
- 110
- Run by
- Centre Antoine Lacassagne
See details and how to joinNCT07633613 · EU 2026-526866-26-00 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- Besancon Cedex, Lyon Cedex 04, Marseille, Rennes Cedex 9, Saint-Herblain, Toulouse
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - No phaseTaking peopleORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Where
- Besançon, Levallois-Perret, Marseille, Neuilly, Paris
- Életkor
- 18 év and over
- People
- 2285 worldwide
- Run by
- Guardant Health, Inc.
See details and how to joinNCT05059444 - No phaseTaking peopleLung cAncer Robotic Comparative Study
- Where
- Marseille, Rouen, Toulouse
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Intuitive Surgical
See details and how to joinNCT06038227 - 1/2. fázisTaking peopleFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Where
- Paris, Villejuif
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00 - No phaseTaking peopleVirus-associated Tumour Microenvironment
- Where
- Paris
- Életkor
- 18 év to 100 év
- People
- 150
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06471296 - 2. fázisTaking peopleStudy Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
- Where
- Bordeaux, Nice, Villejuif
- Életkor
- 18 év and over
- People
- 40
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07016230 - 4. fázisNot yet taking people in FranciaországRandomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
- Where
- Bron, Caluire-et-Cuire, Chevilly-Larue, Dijon, Lille Cedex, Lyon Cedex 04, Marseille, Paris, PARIS, Paris Cedex 20, Pierre-Bénite, Rennes Cedex, Saint-Cloud, Strasbourg Cedex 2, Toulouse, Villejuif
- Életkor
- 65 év and over
- People
- 794
- Run by
- Institut Gustave Roussy
See details and how to join2025-523610-83-00 - 3. fázisTaking peopleRoll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
- Where
- Besancon Cedex, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier Cedex 5, Rennes Cedex, Rouen Cedex, St Herblain, Strasbourg, Toulouse Cedex 9, Tours Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 87 worldwide
- Run by
- Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00 - No phaseTaking peoplePEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC
- Where
- Angers, Le Mans
- Életkor
- 18 év and over
- People
- 75
- Run by
- University Hospital, Angers
See details and how to joinNCT06195527 - 4. fázisNot yet taking people in FranciaországInnovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
- Where
- Villejuif
- Életkor
- 70 év and over
- People
- 794
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07802847 - 2. fázisTaking peopleFIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
- Where
- Aix En Provence, Amiens Cedex 1, Brest Cedex 2, Caen Cedex 5, Créteil, Grenoble Cedex 9, Lille, Limoges Cedex 1, Lorient, Lyon, Lyon Cedex 02, Marseille, Meaux, Mulhouse, Nice, Paris, Paris Cedex 20, Pringy Cedex, Quimper Cedex, Rennes, Strasbourg, Strasbourg Cedex, Toulon Cedex 9, Villefranche Sur Saone Cedex
- Életkor
- 18 év and over
- People
- 80
- Run by
- Centre Leon Berard
See details and how to join2023-506590-35-00 - 1. fázisTaking peopleA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Where
- Bordeaux, Caen, Lille, Lyon, Marseille, Nantes, Nice, Paris, Pierre-Bénite, Poitiers, Toulouse, Villejuif
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT04913285 - 1/2. fázisTaking peopleStudy of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- Where
- Bordeaux, Lyon, Marseille Cedex 5, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06567015 · EU 2023-510203-21-00